Optimizing Outcomes in Schizophrenia
Christoph U. Correll, MD
Associate Professor of Psychiatry
Hofstra North Shore-LIJ School of Medicine
Hempstead, New York
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital
Glen Oaks, New York
Despite multiple therapeutic advances, especially in psychopharmacology, treatment of schizophrenia has remained a major challenge. Not only do clinicians need to ensure that they are optimally and safely treating a patient's psychosis, they also must monitor and treat the patient for various comorbidities. The risks and benefits of any single medication need to be weighed individually with each patient, and that side-effect risk needs to be weight repeatedly during treatment. Side effects need to be continuously monitored and medication adjusted to maintain optimal medical and psychiatric health. As new development and compelling clinical trial data in the management of schizophrenia evolve constantly, clinicians must ensure that they stay abreast of the latest advances and new therapies. In this video, Dr. Christoph Corell reviews dosing strategies to achieve optimal antipsychotic efficacy while minimizing adverse events; antipsychotic switching strategies based on the agents' pharmacodynamic and pharmacokinetic properties; and the evidence for augmentation strategies of antipsychotic monotherapy in schizophrenia.
Method of Participation and Evaluation
To participate in this CME activity, please read the following information and click “Launch Program” at the bottom of this page. The activity may be evaluated online or by downloading the evaluation form by clicking the appropriate button at the bottom of this page. An added benefit of evaluating online is that you may print your certificate immediately after completion of the evaluation. Please note: To view this program you need a computer with an Internet browser and audio and video capabilities.
Up to 1 AMA PRA Category 1 Credit™
This activity is designed for hospital-based psychiatrists, nurse practitioners and physician assistants with strong psychiatric interests, psychiatric residents, and emergency medince healthcare professionals.
After taking part in this CME activity, participants should be able to:
- Formulate a targeted treatment plan that considers symptom response, resolution, remission, recovery, and relapse prevention
- Contrast efficacy and tolerability of individual antipsychotic agents
- Review early antipsychotic agent choice and switch strategies to optimize efficacy and/or tolerability in the treatment of schizophrenia
Christoph U. Correll, MD
Christoph U. Correll, MD, has served as a consultant to Actelion Pharmaceuticals US, Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cephalon, Inc., Intra-Cellular Therapies, Inc., Eli Lilly and Company, Merck & Co., Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Pfizer Inc, Sepracor Inc., and Sunovion Pharmaceuticals Inc.; and has received research grant support from Ortho-McNeil-Janssen Pharmaceuticals, Inc.
The Foundation for Improving Patient Outcomes staff and the independent peer reviewer report nothing to disclose.
CME Credit Designations
ACCME The Foundation for Improving Patient Outcomes (FFIPO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA FFIPO designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AOA This activity is eligible for up to 1 hour of credit in Category 2-A of the American Osteopathic Association.